Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Down 13.0% in September

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 6,090,000 shares, a decline of 13.0% from the September 15th total of 7,000,000 shares. Based on an average daily trading volume, of 1,680,000 shares, the short-interest ratio is currently 3.6 days.

Adaptimmune Therapeutics Trading Down 0.8 %

NASDAQ:ADAP opened at $0.87 on Monday. Adaptimmune Therapeutics has a 12 month low of $0.42 and a 12 month high of $2.05. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $215.13 million, a price-to-earnings ratio of -1.18 and a beta of 2.20. The firm has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.11.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Monday, August 12th. The biotechnology company reported $0.27 EPS for the quarter. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. The company had revenue of $128.23 million during the quarter, compared to the consensus estimate of $58.00 million. Analysts expect that Adaptimmune Therapeutics will post -0.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Long Focus Capital Management LLC increased its stake in Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after purchasing an additional 1,662,184 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after acquiring an additional 394,566 shares in the last quarter. Twin Focus Capital Partners LLC acquired a new stake in shares of Adaptimmune Therapeutics in the 4th quarter worth about $44,000. JTC Employer Solutions Trustee Ltd bought a new position in Adaptimmune Therapeutics in the 1st quarter valued at about $41,000. Finally, Boulder Hill Capital Management LP acquired a new position in Adaptimmune Therapeutics during the 1st quarter valued at about $143,000. Institutional investors own 31.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on ADAP shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Adaptimmune Therapeutics in a research report on Tuesday, August 13th. StockNews.com raised Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.